The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of five new medicines, including Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for noncirrhotic metabolic dysfunction-associated steatohepatitis (NASH), following FDA approval. CHMP has also started re-examination proceedings for Eli Lilly’s Alzheimer’s drug Kisunla, reflecting ongoing regulatory scrutiny. These recommendations mark significant advances in treatment options across metabolic, oncological, and neurological indications within the European market.